Because the majority of cancers rely on the FASN-mediated de novo fatty acid synthesis pathway, FASN could be an attractive therapeutic target, and inhibition of FASN has shown antitumor effects in ovarian cancer (25, 57). This evidence concerns the gene FASN and ovarian carcinoma.